Recruiting studies: Met Amplification

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Phase N/A · 10 location(s) · Novartis Pharmaceuticals · NCT05703516 Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224 A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Ad
Phase 2 · 37 location(s) · AbbVie · NCT07196644 Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Phase 2 · 1 location(s) · Qingdao Central Hospital · NCT07322783 Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-M
Phase 2 · 248 location(s) · SWOG Cancer Research Network · NCT06116682 The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Phase 1/Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06109558 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 44 location(s) · Haihe Biopharma Co., Ltd. · NCT04270591 Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05800340 Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Phase 1/Phase 2 · 12 location(s) · Peking University Cancer Hospital & Institute · NCT07087223 Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unre
Phase 1/Phase 2 · 1 location(s) · Liu Huang · NCT06980532 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Phase 1/Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT06343064 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT06574347 A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doubl
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06829459

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.